QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
QQQ   424.00 (-0.78%)
AAPL   181.61 (+0.03%)
MSFT   399.50 (-0.82%)
META   467.26 (-0.85%)
GOOGL   142.52 (+0.99%)
AMZN   167.99 (+0.54%)
TSLA   193.21 (-0.28%)
NVDA   670.11 (-3.51%)
NIO   6.04 (+1.34%)
AMD   163.81 (-1.13%)
BABA   75.88 (+3.75%)
T   16.96 (+0.30%)
F   12.10 (-1.22%)
MU   80.71 (+0.00%)
CGC   3.39 (-4.24%)
GE   148.32 (-0.20%)
DIS   107.89 (-1.42%)
AMC   4.57 (-1.93%)
PFE   27.49 (-0.36%)
PYPL   57.52 (-1.89%)
XOM   104.53 (+1.73%)
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

$53.58
-1.62 (-2.93%)
(As of 01:22 PM ET)
Today's Range
$52.99
$55.87
50-Day Range
$53.53
$63.86
52-Week Range
$17.05
$64.98
Volume
199,575 shs
Average Volume
385,898 shs
Market Capitalization
$3.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.64

MoonLake Immunotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
35.6% Upside
$72.64 Price Target
Short Interest
Bearish
14.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.10mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$9.19 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.85) to ($1.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.93 out of 5 stars

Medical Sector

551st out of 932 stocks

Pharmaceutical Preparations Industry

253rd out of 431 stocks


MLTX stock logo

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

MLTX Stock Price History

MLTX Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
MLTX Mar 2024 80.000 call
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics Class A
MoonLake Immunotherapeutics: Poised For Acquisition
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
2/21/2024
Next Earnings (Estimated)
3/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.64
High Stock Price Target
$92.00
Low Stock Price Target
$56.00
Potential Upside/Downside
+31.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-49,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.30 per share

Miscellaneous

Free Float
52,910,000
Market Cap
$3.45 billion
Optionable
Optionable
Beta
1.30
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














MLTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price target for 2024?

11 equities research analysts have issued 12 month target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $92.00. On average, they anticipate the company's stock price to reach $72.64 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2024?

MoonLake Immunotherapeutics' stock was trading at $60.39 on January 1st, 2024. Since then, MLTX stock has decreased by 11.3% and is now trading at $53.58.
View the best growth stocks for 2024 here
.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our MLTX earnings forecast
.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) posted its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05.

Who are MoonLake Immunotherapeutics' major shareholders?

MoonLake Immunotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (4.13%), Price T Rowe Associates Inc. MD (3.71%), Price T Rowe Associates Inc. MD (3.71%), Federated Hermes Inc. (1.70%), Finepoint Capital LP (1.43%) and Westfield Capital Management Co. LP (0.98%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Kristian Reich and Matthias Bodenstedt.
View institutional ownership trends
.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLTX) was last updated on 2/21/2024 by MarketBeat.com Staff